Purpose: To evaluate the usefulness of [¹⁸F]-6-fluorodopamine ([¹⁸F]-DA) and [¹⁸F]-L-6-fluoro-3,4-dihydroxyphenylalanine ([¹⁸F]-DOPA) positron emission tomography (PET) in the detection of subcutaneous (s.c.) and metastatic pheochromocytoma in mice; to assess the expression of the norepinephrine transporter (NET) and vesicular monoamine transporters 1 and 2 (VMAT1 and VMAT2), all important for [¹⁸F]-DA and [¹⁸F]-DOPA uptake. Furthermore, to compare tumor detection by micro-computed tomography (microCT) to magnetic resonance imaging (MRI) in individual mouse. Methods: SUVmax values were calculated from [¹⁸F]-DA and [¹⁸F]-DOPA PET, tumor-to-liver ratios (TLR) were obtained and expression of NET, VMAT1 and VMAT2 was evaluated. Results: [¹⁸F]-DA detected less metastatic lesions compared to [¹⁸F]-DOPA. TLR values for liver metastases were 2.26–2.71 for [¹⁸F]-DOPA and 1.83–2.83 for [¹⁸F]-DA. A limited uptake of [¹⁸F]-DA was found in s.c. tumors (TLR=0.22-0.27) compared to [¹⁸F]-DOPA (TLR=1.56-2.24). Overall, NET and VMAT2 were expressed in all organ and s.c. tumors. However, s.c. tumors lacked expression of VMAT1. We confirmed [¹⁸F]-DA's high affinity for the NET for its uptake and VMAT1 and VMAT2 for its storage and retention in pheochromocytoma cell vesicles. In contrast, [¹⁸F]-DOPA was found to utilize only VMAT2. Conclusion: MRI was superior in the detection of all organ tumors compared to microCT and PET. [¹⁸F]-DOPA had overall better sensitivity than [¹⁸F]-DA for the detection of metastases. Subcutaneous tumors were localized only with [¹⁸F]-DOPA, a finding that may reflect differences in expression of VMAT1 and VMAT2, perhaps similar to some patients with pheochromocytoma where [¹⁸F]-DOPA provides better visualization of lesions than [¹⁸F]-DA.